The full drug name of Dagliflozin is Dagliflozin Tablets, and patients with cirrhosis may take this product under the supervision of a physician on medical advice if they meet the indications for its use, but Dagliflozin does not improve the symptoms of cirrhosis. Dagliflozin tablets are used for the treatment of diabetes mellitus and can be used as monotherapy for adult patients with type 2 diabetes mellitus to improve glycemic control on the basis of diet and exercise. It has no hepatic impairment effect and no dose adjustment is required for patients with mild, moderate or severe hepatic impairment, and patients with cirrhosis can take this product under the supervision of a physician as prescribed by a doctor. It should be noted that some patients taking this product may develop hypotension, ketoacidosis, acute kidney injury and renal impairment, urinary sepsis and pyelonephritis, genital fungal infections and other adverse reactions, therefore, allergic to this product and patients with severe renal impairment, end-stage renal disease or the need for dialysis should be prohibited.